Chapter 031

Insulin, Oral Hypoglycemics, and Glucagon

Gail T. Galasko

GENERAL REFERENCES

  1. An inhaled insulin (Afrezza), Med Lett Drugs Therap 57(1463):34–35, 2015. PUBMED Abstract
  2. Davidson JA: The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes, Endocrine Pract 19:1050–1061, 2013. PUBMED Abstract
  3. De Meyts P, Sajid W, Palsgaard J, et al.: Insulin and IGF-I receptor structure and binding mechanisms. In Mechanisms of Insulin Action, New York, 2007, Springer, pp 1–32. PUBMED Abstract
  4. Drugs for type 2 diabetes, Med Lett Drugs Therap 12(139):17–24, March 2014. PUBMED Abstract
  5. Ferrannini E: The target of metformin in type 2 diabetes, N Engl J Med 371:1547–1548, 2014. PUBMED Abstract
  6. Hardie DG: AMP-activated protein kinase as a drug target, Ann Rev Pharmacol Toxicol 47:185–210, 2006. PUBMED Abstract
  7. Scheen A: Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes, Drugs 75:33–59, 2015. PUBMED Abstract
  8. Tornio A, Niemi M, Neuvonem PJ, Backman JT: Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications, Trends Pharmacol Sci 33:312–322, 2012. PUBMED Abstract
  9. Vallon V: The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus, Ann Rev Med 66:255–270, 2015. PUBMED Abstract